Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

microsampling

  • Home
  •  
  • microsampling



  • Most Read
  • Latest Comments
  • Trajan sees demand for life science products soften, hopeful for rebound next year
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Trajan sees demand for life science products soften, hopeful for rebound next year
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Trajan sees demand for life science products soften, hopeful for rebound next year
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Trajan sees demand for life science products soften, hopeful for rebound next year
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Trajan sees demand for life science products soften, hopeful for rebound next year
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Trajan sees demand for life science products soften, hopeful for rebound next year
    Trajan sees demand for life science products soften, hopeful for rebound next year
    • News

  • SciDev to provide water treatment solutions to Ventia in $2m revenue opportunity
    SciDev to provide water treatment solutions to Ventia in $2m revenue opportunity
    • News

  • Trajan sees demand for life science products soften, hopeful for rebound next year
    • News

    Trajan sees demand for life science products soften, hopeful for rebound next year

    Melbourne-based developer and manufacturer of analytical and life sciences products Trajan Group (ASX: TRJ) expects its full-year revenue for FY24 to fall short of previous projections due to delays in order delivery and unexpected softening in the pharmaceutical sector.  Trajan manufactures analytical and life sciences products and devices—including microscope slides, analytical syringes and micro-sampling tools

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.